Herein, CHPA provides feedback on the Food and Drug Administration’s Nutrition Innovation Strategy, particularly as it relates to the agency’s development and implementation of a consumer education campaign.
Today, the Consumer Healthcare Products Association (CHPA) issued the following statement upon submitting comments to the Food and Drug Administration (FDA) regarding its draft guidance titled, “Innovative Approaches for Nonprescription Drug Products.”
CHPA members look forward to publication of the final guidance and the companion proposed rule. Together these regulatory documents will provide insights that sponsors can consider when designing research and development proposals for Rx to OTC switch programs.
CHPA applauds Colorado for enacting a law prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors this week.
CHPA applauds the House of Representatives’ passage of legislation that will restore consumers’ ability to use their HSAs and FSAs to purchase over-the-counter medicines and feminine hygiene products.
CHPA is pleased to see FDA’s long-awaited draft guidance on innovative approaches for greater consumer access to nonprescription medicines, and applauds FDA’s focus on patient safety as a top priority.
CHPA is pleased to see FDA’s long-awaited draft guidance on innovative approaches for greater consumer access to nonprescription medicines, and applauds FDA’s focus on patient safety as a top priority.
Herein, CHPA provides feedback on the Agricultural Marketing Service (AMS) request for comments on a Proposed Rule to establish the national mandatory bioengineered food disclosure standard.
